News

DEA's 2027 Production Quotas Preview the First Schedule III Marijuana Quotas

DEA's 2027 quota proposal says a separate notice will set the first schedule III marijuana quotas. Comments on the schedule I and II proposal are due Dec. 10.
Compliance Carl
8
 Min Read
Published
November 19, 2026
Updated on:
November 19, 2026
Glass measuring scale beside the headline DEA Previews Schedule III Marijuana Quotas
Regulatory Topics
Regulation & Compliance Locations Covered in Post:
Cannabinoids & Compounds Covered in Post:
Relevant Readers:
explore all cannabis and hemp regulations

Quick Answer

  • DEA will propose the first schedule III marijuana quotas in a separate Federal Register notice. The proposed 2027 aggregate production quotas, published Nov. 10, 2026 (91 FR 72566, Docket No. DEA-1730P), give no date or size for that proposal.
  • The current proposal covers schedules I and II only, under 21 U.S.C. 826. Its schedule I figures are 6,675,000 grams for marijuana, 1,000,000 grams for marijuana extract and 1,523,040 grams for delta-9-THC.
  • The schedule III quota rests on the Single Convention, not the quota statute. The April 2026 order (91 FR 22714) says state-licensed marijuana will have to meet treaty quota requirements. The mechanics for applying and for cutting individual quotas have not been published.
  • Comments are due on or before Dec. 10, 2026. Electronic filings close at 11:59 p.m. Eastern. Manufacturers seeking DEA registration should watch the Federal Register for the schedule III notice and plan for individual quota requests.

The Drug Enforcement Administration's proposed 2027 aggregate production quotas, published Nov. 10, 2026 (FR Doc. 2026-22843, Docket No. DEA-1730P, 91 FR 72566), say the first quotas for schedule III marijuana will come in a separate Federal Register notice. Comments on the schedule I and II proposal are due on or before Dec. 10, 2026. The notice gives no date for the schedule III proposal and does not say how big it will be.

On this page

What DEA proposed for 2027

An aggregate production quota, or APQ, is the total amount of a controlled substance DEA allows to be manufactured in the United States in a calendar year. Under 21 U.S.C. 826, DEA sets APQs for each basic class of controlled substance in schedules I and II, then hands out individual manufacturing quotas to registered manufacturers. The individual quotas cannot add up to more than the aggregate.

The 2027 proposal sets these schedule I figures for cannabis substances, in grams:

  • Marijuana: 6,675,000 grams.
  • Marijuana extract: 1,000,000 grams.
  • Delta-9-tetrahydrocannabinol: 1,523,040 grams.
  • All other tetrahydrocannabinol: 1,166,130 grams.

DEA says that table covers only schedule I marijuana, marijuana extract and delta-9-THC (drug codes 7360, 7350 and 7370). The schedule III versions of the same substances have their own drug codes: 7362 for marijuana, 7353 for marijuana extract and 7386 for naturally derived delta-9-THC. For those, DEA wrote, "A separate notice will be published in the Federal Register" once the proposed amounts are determined. DEA says it is still registering schedule III manufacturers and distributors and choosing data sets to estimate legitimate need.

Two processes now run side by side, and they bind different people. The Dec. 10 comment window governs research and pharmaceutical supply that stays in schedule I. For a manufacturer that wants to make product for state medical programs under a DEA registration, the number that will matter is the one in the schedule III notice that has not been published yet.

Why marijuana now sits in two tables

The split traces to the April 2026 rescheduling order. The final order at 91 FR 22714 (FR Doc. 2026-08176, effective April 28, 2026) placed three entries in schedule III: marijuana, marijuana extract and naturally derived delta-9-THC, each only when it is in an FDA-approved product or subject to a state medical marijuana license. Everything else, including unlicensed and bulk marijuana, "remains a schedule I controlled substance." That is the line behind the two-tier federal market for medical and recreational cannabis.

ItemSchedule I marijuanaSchedule III marijuana
What it coversMarijuana, extract and delta-9-THC outside an FDA-approved product or a state medical marijuana license, including unlicensed and bulk materialMarijuana, extract and naturally derived delta-9-THC in an FDA-approved product or subject to a state medical marijuana license
DEA drug codes7360 marijuana, 7350 marijuana extract, 7370 delta-9-THC7362 marijuana, 7353 marijuana extract, 7386 naturally derived delta-9-THC
2027 quota statusProposed Nov. 10, 2026: 6,675,000 g marijuana; 1,000,000 g extract; 1,523,040 g delta-9-THC. Comments due Dec. 10, 2026Not yet proposed. DEA says a separate notice will follow; no date given
Legal hook for the quota21 U.S.C. 826 (schedules I and II)Single Convention quota obligation, as described in the April 2026 order and the APQ notice
Registration pathStandard DEA schedule I registrationExpedited registration for state medical marijuana licensees under 21 CFR 1301.13(k), limited to the scope of the state license

This is the part the wire stories skipped. The quota statute, 21 U.S.C. 826, reaches schedules I and II. Schedule III drugs normally carry no production ceiling. The April order explains why rescheduled marijuana does: the 1961 Single Convention on Narcotic Drugs requires licensed manufacturers of its schedule I drugs, which include cannabis, to obtain quotas. The order says state-licensed marijuana will have to meet those treaty quota requirements. The order itself rested on 21 U.S.C. 811(d)(1), which lets the government schedule a drug by order to carry out treaty obligations.

The APQ notice repeats the treaty rationale but does not cite a statutory provision for setting quotas on a schedule III substance. That leaves an open question for registrants: rescheduled medical marijuana keeps a schedule II style production ceiling, but the mechanics (who applies, by when, and how individual quotas are cut if demand exceeds the aggregate) have not been published.

Why it isn't settled

Nothing about the schedule III quota is fixed: no number, no date, no chosen data source. A quota sized to research demand would look very different from one sized to state medical program sales.

The broader rescheduling case is also open. The administrative hearing record closed with final briefs on Nov. 5, as covered in our report on the rescheduling hearing record. As of Nov. 18, DEA's rescheduling docket page showed no recommended decision from the administrative law judge. DEA's own position on the record is laid out in DEA's schedule III post-hearing brief.

What operators should check

  • Manufacturers seeking DEA registration. Watch the Federal Register for the schedule III APQ notice and plan for individual quota requests. The failure mode is building capacity for state demand that a federal ceiling will not cover.
  • Registered dispensaries. Your supply now has to come from federally registered sources, as covered in our guide to the Nov. 29 supply-chain deadline. A tight manufacturer quota would narrow that pool.
  • Researchers and pharmaceutical developers. The Dec. 10 comment window is the scheduled chance to argue that the schedule I research figures are too low.
  • Tax and finance teams. Schedule III status matters for 280E, but only for activity that actually sits in schedule III. See the 280E schedule III playbook before assuming the whole business qualifies.
  • Multistate operators. Map which licenses in which states are medical licenses DEA accepts. A quota will only meter supply for registrants that get through registration.
  • Before filing comments. Comments filed in the docket may be posted publicly. Decide what operating data you are willing to disclose, and talk to your counsel.

How states diverge on the way in

The quota will meter a system that states are entering on very different terms. In California, the Department of Cannabis Control adopted emergency regulations on June 5, 2026 letting retailers holding a combined A and M license split it so the medical side can seek DEA registration; the follow-on rulemaking, DCC-2026-04-R, is covered in our piece on California's A/M license split. Even so, Marijuana Moment reported on Nov. 11 that DEA sent orders to show cause to at least some California applicants, citing sources and documents it reviewed, on the ground that California does not require a physician's written certification.

In Minnesota, Marijuana Moment reported on Oct. 30 that DEA issued an order to show cause to a Minneapolis dispensary, saying the state's dual-purpose license falls outside the federal definition of a state medical license. The same report said businesses in states such as Florida and Texas were among the more than 900 approved. Operationally, a state's license design now decides whether its operators are inside the schedule III supply chain at all, before any quota question arises.

What's next

  • Nov. 29, 2026: Supply-chain deadline for DEA-registered medical marijuana dispensaries.
  • Dec. 1, 2026: Annual statutory date under 21 U.S.C. 826(c) for registered manufacturers to apply for individual manufacturing quotas for schedule I and II substances.
  • Dec. 10, 2026: Comments due on the proposed 2027 schedule I and II APQs, Docket No. DEA-1730P, by 11:59 p.m. Eastern for electronic filings.

Frequently asked questions

What is a DEA aggregate production quota?

It is the total amount of a schedule I or II controlled substance DEA allows to be manufactured in the United States in a year, set under 21 U.S.C. 826. Individual manufacturing quotas for registered manufacturers are allotted from it and cannot exceed it.

Will schedule III marijuana have a production quota?

Yes, according to DEA. Its proposed 2027 quotas notice says a separate Federal Register notice will propose quotas for schedule III marijuana, marijuana extract and naturally derived delta-9-THC (drug codes 7362, 7353 and 7386). No date has been given.

When are comments due on DEA's 2027 production quotas?

Comments on the proposed 2027 schedule I and II quotas (Docket No. DEA-1730P, published Nov. 10, 2026) are due on or before Dec. 10, 2026. Electronic comments close at 11:59 p.m. Eastern that day.

Does this affect state adult-use marijuana?

Not directly. Under the April 2026 order, only marijuana in FDA-approved products or subject to a state medical marijuana license moved to schedule III. Adult-use marijuana remains in schedule I federally, and the coming schedule III quotas would cover medical marijuana handled by DEA registrants. Talk to your counsel.

Sources

This is regulatory journalism, not legal advice. Talk to your counsel.

Compliance Carl
Senior Compliance Editor
Compliance Carl is the senior editor desk at CannabisRegulations.ai. Carl writes about federal scheduling, state enforcement, carrier policy, and the operational compliance questions cannabis and hemp businesses actually face.

Featured Compliance Insights